GO
Loading...

Merck & Co Inc

More

  • TRENTON, N.J.— One of the hot new cancer immunotherapy drugs, Merck& Co.' s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer Research conference in Philadelphia. One study, comparing Keytruda to Bristol-Myers Squibb Co.' s Yervoy, could give Merck...

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • LONDON, April 15- Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move-- quite literally. Chief Executive Pascal Soriot is making AstraZeneca more nimble as hopes build for its cancer pipeline, but he still has his work cut out to keep 2015 earnings above the floor needed to protect his...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza and Takeda Pharmaceutical Co.' s rival product Nesina should carry information about the risk of heart failure, an advisory committee to the U.S. Food and Drug Administration said on Tuesday. The panel reviewed safety data on AstraZeneca's Onglyza and Takeda's Nesina. The studies were requested by...

  • A preliminary FDA review of Nesina, or alogliptin, showed a numerical increase in heart failure hospitalizations but not a statistically significant increase. Even so, some analysts expect the FDA to treat all drugs in the class the same way. "We believe the FDA will likely view the risk as likely to be a class effect and apply changes to all approved drugs in the...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza should include new safety information about the risk of heart failure, a U.S. Food and Drug Administration advisory panel concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. A preliminary FDA review of the drug published on Friday noted an...

  • FDA panel wants heart failure risk on AstraZeneca drugs Tuesday, 14 Apr 2015 | 12:56 PM ET

    WASHINGTON— Federal health advisers say AstraZeneca's Onglyza and a related diabetes drug should carry new information about a possible association with heart failure and death. The FDA convened Tuesday's meeting to review data from a 16,000- patient study looking at Onglyza and Kombiglize's heart safety. AstraZeneca's study did not show links to heart...

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks closed higher, with the Dow above 18,000 for the first time in April as investors looked ahead to the official start of earnings season.

  • April 10- AstraZeneca Plc's diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration. The FDA's report, posted on the agency's website on Friday, comes ahead of an April 14 meeting of an FDA advisory panel to discuss the drug's safety. The FDA said the causes of death...

  • *Index Ventures clocks up 11 transactions since 2005. Ten years on from pioneering an ultra-lean business model focused on investing in "virtual" companies with a single experimental medicine, XO1's backer Index Ventures is chalking up some notable wins. The new model has grabbed attention as venture capitalists strive to improve returns in a notoriously...

  • Early movers: RDSA, TSLA, MRK, RAD & more Wednesday, 8 Apr 2015 | 8:02 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Merck's potential HCV drug gets special FDA designation Wednesday, 8 Apr 2015 | 7:26 AM ET

    NEW YORK— Merck& Co. said Wednesday that the Food and Drug Administration granted the pharmaceutical company's developing hepatitis C treatment two special designations. The FDA granted Merck's grazoprevir/elbasvir combination "breakthrough therapy designation" for two different types of the condition, which affects the liver. The Kenilworth, New...

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks closed higher, rebounding from initial losses on the disappointing jobs report as weak data renewed hopes of a rate hike delay.

  • Biotech wins $45 million grant for Ebola vaccine Monday, 6 Apr 2015 | 9:28 AM ET
    Dr. Joseph Kim, founder of Inovio Pharmaceuticals

    Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.

  • Stocks close moderately lower on mixed data Wednesday, 1 Apr 2015 | 4:00 PM ET
    A trader works on the floor of the New York Stock Exchange.

    U.S. stocks closed lower on Wednesday as investors weighed softness in economic data ahead of Friday's important jobs report.

  • FRANKFURT, April 1- Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive said. Roche is vying with rivals such as Bristol-Myers Squibb, Merck& Co and AstraZeneca to develop such immuno-oncology therapies that harness the power of the body's immune...

  • An outbreak of Ebola killed close to 10,000 people across West Africa over the last year, with Liberia, Guinea and Sierra Leone being the worst affected. Private company Mapp Biopharmaceutical and Tekmira Pharmaceuticals Corp have shown that their Ebola drugs could cure non-human primates. The other companies that are currently testing potential...

  • Lightning Round: Stay far away from this Friday, 27 Mar 2015 | 7:09 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks plunged, closing more than 1 percent lower as investors weighed the impact of the strong dollar on the economy and earnings.

  • Merck increases share buyback plan   Wednesday, 25 Mar 2015 | 10:18 AM ET
    Merck increases share buyback plan

    The New Jersey-based drug giant buys back $10 billion worth of its own shares. CNBC's Landon Dowdy reports.